Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mei Chen

Nurse Practitioner, Primary Care Houston, TX Nurse Practitioner

NPI 1548588189 CMS profile 10551443

1125 Cypress Station Dr Ste F1, Houston, TX 77090

Open in the dashboard

General payments

$4,220

178 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mei Chen of Houston, TX is reported in the CMS Open Payments database as having received $4,220 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,161 33
2024 General $1,004 46
2023 General $1,083 47
2022 General $400 18
2021 General $572 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mei Chen
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Mei Chen were reported at $1,161. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Mei Chen Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $572 $137 $39–$445 $132
2022 $400 $139 $44–$421 $149
2023 $1,083 $163 $53–$481 $160
2024 $1,004 $176 $54–$511 $164
2025 $1,161 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lexicon Pharmaceuticals, Inc. $465 25 payments
  2. Merck Sharp & Dohme Corporation $373 22 payments
  3. Boston Scientific Corporation $334 10 payments
  4. Janssen Pharmaceuticals, Inc $327 18 payments
  5. Esperion Therapeutics, Inc. $294 16 payments
  6. Novartis Pharmaceuticals Corporation $273 14 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $266 5 payments
  8. BridgeBio Pharma, Inc. $206 3 payments
  9. Abiomed $184 3 payments
  10. Sequel Med Tech, LLC $172 1 payment
  11. Other $1,327 61 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,220 178 payments
Products named General payments · program years 2021–2025
  1. VERQUVO $439 27 payments
  2. XARELTO $327 18 payments
  3. Inpefa $323 15 payments
  4. WATCHMAN Access System $297 9 payments
  5. NEXLETOL $294 16 payments
  6. Kerendia $247 4 payments
  7. Attruby $206 3 payments
  8. TWIIST $172 1 payment
  9. OPTIMIZER Cardiovascular Device $163 1 payment
  10. OPTIMIZER Cardiovascular Device $163 1 payment
  11. Other $2,026 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record